COPENHAGEN, May 7 (Reuters) - Obesity drugmaker Novo Nordisk NOVOb.CO on Wednesday posted first-quarter operating profit above analyst forecasts and cut its operating profit and sales outlook for the year.
PREVIEW-Novo Nordisk's stellar Wegovy-fuelled run of hiking sales guidance could be ending nL1N3R20FX
EXCLUSIVE-US pharma tariffs would raise US drug costs by $51 billion annually, report finds nL1N3R30N9
Novo shares on track for biggest monthly fall since 2002, investor worries grow nL2N3QA0Z8
Novo Nordisk's new obesity drug trial data disappoints again nL1N3PT0AR